Thirumalai Chemicals Limited has informed the Exchange about Corporate Presentation
TIRUMALCHM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thirumalai Chemicals shared its Q1 FY26 investor presentation with the exchanges, covering business overview, financials, USA expansion updates, and ESG goals. Q1 FY26 was a weak quarter with consolidated total income at Rs 452 Cr (down 19% YoY) and consolidated EBITDA turning negative at Rs -25 Cr versus Rs 34 Cr a year ago; consolidated PAT swung to a loss of Rs 60 Cr from a profit of Rs 5 Cr in Q1 FY25. Standalone performance also deteriorated sharply, with EBITDA falling 87% YoY to Rs 7 Cr and PAT turning negative at Rs -14 Cr, hurt by lower product spreads, soft export volumes, and higher finance costs tied to USA project borrowings. The 40 KTPA Maleic Anhydride project in West Virginia, USA (~$240 million capex) remains on track for first product by December 2025, with civil work fully complete, key equipment erected, and the boiler hydro test planned for August 2025. The company reiterated its medium-term goal of generating 50% of EBITDA from high-margin Maleic Anhydride and downstream value-added products.
Near-term earnings are under pressure from weak global spreads, soft demand, and higher interest costs, which is a headwind for the stock. The upcoming USA plant commissioning and the shift toward value-added products are the key longer-term positives to watch.